EMA provides product-specific bioequivalence guidance

EMA for the first time released product-specific Xeloda capecitabine from Roche (SIX:ROG; OTCQX:RHHBY), Sprycel dasatinib from Bristol-Myers Squibb Co. (NYSE:BMY), Tarceva erlotinib from Astellas Phar...